Two More Diabetes Drugs in Trouble This Week

Two of the newest diabetes treatments suffered major set-backs this week. Endocrinologists across the U.S. received a notice today that Exubera, the inhaled form of insulin, would soon become unavailable. This is because Pfizer, the pharmaceutical giant which has sole...